Resource Library
Overcoming cell line development challenges through early-stage assessment and management
Cell line development (CLD) timelines, product quality, and drug stability continue to impose difficult bottlenecks that disrupt clinical trials, bringing attention to CLD practices and opportunities to achieve faster timelines. In this whitepaper, we discuss how to overcome the challenges in cell line development through early-stage assessment and management. We also share how Samsung Biologics balances quality and titer through the application of high-throughput analytic methods to cut risk, time, and cost.
Cell line development (CLD) timelines, product quality, and drug stability continue to impose difficult bottlenecks that disrupt clinical trials, bringing attention to CLD practices and opportunities to achieve faster timelines. In this whitepaper, we discuss how to overcome the challenges in cell line development through early-stage assessment and management. We also share how Samsung Biologics balances quality and titer through the application of high-throughput analytic methods to cut risk, time, and cost.